NCIC CTG to sponsor, conduct colorectal cancer study for Oncolytics

Friday, May 4, 2012 04:36 PM

Calgary, Alberta-based Oncolytics Biotech has chosen NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, to sponsor and conduct a randomized phase II study of Reolysin in patients with advanced or metastatic colorectal cancer.

"We are pleased to be conducting a second randomized study with the NCIC CTG," said Brad Thompson, president and CEO of Oncolytics. "This study will build on both our early preclinical and clinical colorectal cancer work, as well as preclinical research combining Reolysin with Avastin. As a company, we intend to continue expanding our clinical program to  include randomized studies of frequently diagnosed cancers."

The study will be an open-label, randomized, non-blinded, phase II clinical study of Reolysin given in combination with Folfox-6 plus bevacizumab (Avastin) versus Folfox-6 plus bevacizumab alone. Approximately 50 response evaluable patients will be enrolled in each arm, after a six to nine patient safety run in.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs